For comments, suggestions
Created with Raphaël 2.1.0 01.08.2016 Filing date 28.02.2018 Validation fee payment 31.07.2018 (A1) Patent application published 24.04.2023 AGEPI application filing date 30.06.2023 (T2) Translation of the validated European patent 25.05.2025 01.08.2025 Valid until 02.08.2026 Renewal fee to be paid until 01.08.2036 Patent will expire on

Patent in force


(210)Number of the EPO application16756952
(220)Filing date of the EPO application2016.08.01
(80)EPO patent specification publication (B)EPB nr. 08/2023, 2023.02.22
(110)EPO patent number3328891
(11)Number of the documentMD 3328891 T2
(21)Number of the applicatione 2018 0564
(71)Name(s) of applicant(s), code of the countryAmgen Research (Munich) GmbH, DE;
(72)Name(s) of inventor(s), code of the countryRAUM Tobias, DE;
PENDZIALEK Jochen, DE;
BLUEMEL Claudia, DE;
BOTT Franziska, DE;
DAHLHOFF Christoph, DE;
HOFFMANN Patrick, DE;
NAHRWOLD Elisabeth, DE;
MUENZ Markus, DE;
BROZY Johannes, DE;
KUFER Peter, DE;
FRIEDRICH Matthias, DE;
RATTEL Benno, DE;
BOGNER Pamela, DE;
WOLF Andreas, DE;
POMPE Cornelius, DE;
(73)Name(s) of owner(s), code of the countryAMGEN Research (Munich) GmbH, DE;
(54)Title of the inventionAntibody constructs for FLT3 and CD3
(13)Kind-of-document code T2
(51)International Patent Classification C07K 16/28 (2006.01.01); C07K 16/46 (2006.01.01)
(19)CountryDE
(41)Date of publication of the application2018.07.31
(49)Date of publication of the translation of the validated European patent specification2023.06.30
(30)Priority201562199944 P, 2015.07.31, US; 201662290861 P, 2016.02.03, US
(74)Patent attorney(Procedură) CORCODEL Angela, Bd. Ştefan cel Mare nr. 134, Chişinău, Republica Moldova
(86)International applicationPCT/EP2016/068319, 2016.08.01
(87)International publicationWO 2017/021362, 2017.02.09
Up
/Inventions/details/3328891